Report cover image

Global Neurofibromatoses Type II Therapecutics Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 99 Pages
SKU # APRC20548657

Description

Summary

According to APO Research, The global Neurofibromatoses Type II Therapecutics market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Neurofibromatoses Type II Therapecutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Neurofibromatoses Type II Therapecutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Neurofibromatoses Type II Therapecutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Neurofibromatoses Type II Therapecutics include AstraZeneca Plc, Recursion Pharmaceuticals Inc, Plex Pharmaceuticals Inc, Lixte Biotechnology Holdings Inc, Beta Pharma Inc and Arno Therapeutics Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Neurofibromatoses Type II Therapecutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurofibromatoses Type II Therapecutics.
The Neurofibromatoses Type II Therapecutics market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurofibromatoses Type II Therapecutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Neurofibromatoses Type II Therapecutics Segment by Company

AstraZeneca Plc
Recursion Pharmaceuticals Inc
Plex Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
Beta Pharma Inc
Arno Therapeutics Inc
Neurofibromatoses Type II Therapecutics Segment by Type

LB-205
LB-201
Icotinib Hydrochloride
FRAX-597
AR-42
Others
Neurofibromatoses Type II Therapecutics Segment by Application

Clinic
Hospital
Home Care
Neurofibromatoses Type II Therapecutics Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurofibromatoses Type II Therapecutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurofibromatoses Type II Therapecutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurofibromatoses Type II Therapecutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurofibromatoses Type II Therapecutics manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Neurofibromatoses Type II Therapecutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

99 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Neurofibromatoses Type II Therapecutics Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Neurofibromatoses Type II Therapecutics Sales Estimates and Forecasts (2020-2031)
1.3 Neurofibromatoses Type II Therapecutics Market by Type
1.3.1 LB-205
1.3.2 LB-201
1.3.3 Icotinib Hydrochloride
1.3.4 FRAX-597
1.3.5 AR-42
1.3.6 Others
1.4 Global Neurofibromatoses Type II Therapecutics Market Size by Type
1.4.1 Global Neurofibromatoses Type II Therapecutics Market Size Overview by Type (2020-2031)
1.4.2 Global Neurofibromatoses Type II Therapecutics Historic Market Size Review by Type (2020-2025)
1.4.3 Global Neurofibromatoses Type II Therapecutics Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2020-2025)
1.5.2 Europe Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2020-2025)
1.5.4 South America Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Neurofibromatoses Type II Therapecutics Industry Trends
2.2 Neurofibromatoses Type II Therapecutics Industry Drivers
2.3 Neurofibromatoses Type II Therapecutics Industry Opportunities and Challenges
2.4 Neurofibromatoses Type II Therapecutics Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Neurofibromatoses Type II Therapecutics Revenue (2020-2025)
3.2 Global Top Players by Neurofibromatoses Type II Therapecutics Sales (2020-2025)
3.3 Global Top Players by Neurofibromatoses Type II Therapecutics Price (2020-2025)
3.4 Global Neurofibromatoses Type II Therapecutics Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Neurofibromatoses Type II Therapecutics Major Company Production Sites & Headquarters
3.6 Global Neurofibromatoses Type II Therapecutics Company, Product Type & Application
3.7 Global Neurofibromatoses Type II Therapecutics Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Neurofibromatoses Type II Therapecutics Market CR5 and HHI
3.8.2 Global Top 5 and 10 Neurofibromatoses Type II Therapecutics Players Market Share by Revenue in 2024
3.8.3 2023 Neurofibromatoses Type II Therapecutics Tier 1, Tier 2, and Tier 3
4 Neurofibromatoses Type II Therapecutics Regional Status and Outlook
4.1 Global Neurofibromatoses Type II Therapecutics Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Neurofibromatoses Type II Therapecutics Historic Market Size by Region
4.2.1 Global Neurofibromatoses Type II Therapecutics Sales in Volume by Region (2020-2025)
4.2.2 Global Neurofibromatoses Type II Therapecutics Sales in Value by Region (2020-2025)
4.2.3 Global Neurofibromatoses Type II Therapecutics Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Neurofibromatoses Type II Therapecutics Forecasted Market Size by Region
4.3.1 Global Neurofibromatoses Type II Therapecutics Sales in Volume by Region (2026-2031)
4.3.2 Global Neurofibromatoses Type II Therapecutics Sales in Value by Region (2026-2031)
4.3.3 Global Neurofibromatoses Type II Therapecutics Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Neurofibromatoses Type II Therapecutics by Application
5.1 Neurofibromatoses Type II Therapecutics Market by Application
5.1.1 Clinic
5.1.2 Hospital
5.1.3 Home Care
5.2 Global Neurofibromatoses Type II Therapecutics Market Size by Application
5.2.1 Global Neurofibromatoses Type II Therapecutics Market Size Overview by Application (2020-2031)
5.2.2 Global Neurofibromatoses Type II Therapecutics Historic Market Size Review by Application (2020-2025)
5.2.3 Global Neurofibromatoses Type II Therapecutics Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Neurofibromatoses Type II Therapecutics Sales Breakdown by Application (2020-2025)
5.3.2 Europe Neurofibromatoses Type II Therapecutics Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Breakdown by Application (2020-2025)
5.3.4 South America Neurofibromatoses Type II Therapecutics Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 AstraZeneca Plc
6.1.1 AstraZeneca Plc Comapny Information
6.1.2 AstraZeneca Plc Business Overview
6.1.3 AstraZeneca Plc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AstraZeneca Plc Neurofibromatoses Type II Therapecutics Product Portfolio
6.1.5 AstraZeneca Plc Recent Developments
6.2 Recursion Pharmaceuticals Inc
6.2.1 Recursion Pharmaceuticals Inc Comapny Information
6.2.2 Recursion Pharmaceuticals Inc Business Overview
6.2.3 Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Portfolio
6.2.5 Recursion Pharmaceuticals Inc Recent Developments
6.3 Plex Pharmaceuticals Inc
6.3.1 Plex Pharmaceuticals Inc Comapny Information
6.3.2 Plex Pharmaceuticals Inc Business Overview
6.3.3 Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Portfolio
6.3.5 Plex Pharmaceuticals Inc Recent Developments
6.4 Lixte Biotechnology Holdings Inc
6.4.1 Lixte Biotechnology Holdings Inc Comapny Information
6.4.2 Lixte Biotechnology Holdings Inc Business Overview
6.4.3 Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Product Portfolio
6.4.5 Lixte Biotechnology Holdings Inc Recent Developments
6.5 Beta Pharma Inc
6.5.1 Beta Pharma Inc Comapny Information
6.5.2 Beta Pharma Inc Business Overview
6.5.3 Beta Pharma Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Beta Pharma Inc Neurofibromatoses Type II Therapecutics Product Portfolio
6.5.5 Beta Pharma Inc Recent Developments
6.6 Arno Therapeutics Inc
6.6.1 Arno Therapeutics Inc Comapny Information
6.6.2 Arno Therapeutics Inc Business Overview
6.6.3 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Product Portfolio
6.6.5 Arno Therapeutics Inc Recent Developments
7 North America by Country
7.1 North America Neurofibromatoses Type II Therapecutics Sales by Country
7.1.1 North America Neurofibromatoses Type II Therapecutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Neurofibromatoses Type II Therapecutics Sales by Country (2020-2025)
7.1.3 North America Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2026-2031)
7.2 North America Neurofibromatoses Type II Therapecutics Market Size by Country
7.2.1 North America Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Neurofibromatoses Type II Therapecutics Market Size by Country (2020-2025)
7.2.3 North America Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Neurofibromatoses Type II Therapecutics Sales by Country
8.1.1 Europe Neurofibromatoses Type II Therapecutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Neurofibromatoses Type II Therapecutics Sales by Country (2020-2025)
8.1.3 Europe Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2026-2031)
8.2 Europe Neurofibromatoses Type II Therapecutics Market Size by Country
8.2.1 Europe Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Neurofibromatoses Type II Therapecutics Market Size by Country (2020-2025)
8.2.3 Europe Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Neurofibromatoses Type II Therapecutics Sales by Country
9.1.1 Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Neurofibromatoses Type II Therapecutics Sales by Country (2020-2025)
9.1.3 Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Neurofibromatoses Type II Therapecutics Market Size by Country
9.2.1 Asia-Pacific Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Neurofibromatoses Type II Therapecutics Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Neurofibromatoses Type II Therapecutics Sales by Country
10.1.1 South America Neurofibromatoses Type II Therapecutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Neurofibromatoses Type II Therapecutics Sales by Country (2020-2025)
10.1.3 South America Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2026-2031)
10.2 South America Neurofibromatoses Type II Therapecutics Market Size by Country
10.2.1 South America Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Neurofibromatoses Type II Therapecutics Market Size by Country (2020-2025)
10.2.3 South America Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Country
11.1.1 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Country (2020-2025)
11.1.3 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size by Country
11.2.1 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Neurofibromatoses Type II Therapecutics Value Chain Analysis
12.1.1 Neurofibromatoses Type II Therapecutics Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Neurofibromatoses Type II Therapecutics Production Mode & Process
12.2 Neurofibromatoses Type II Therapecutics Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Neurofibromatoses Type II Therapecutics Distributors
12.2.3 Neurofibromatoses Type II Therapecutics Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.